I型高脂血症治療薬の世界市場レポート2020

• 英文タイトル：Global Type I Hyperlipoproteinemia Drug Sales Market Report 2020

• レポートコード：MRC2102QY15547 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療

• 販売価格（消費税別）

Single User	￥600,000 (USD4,000)	▷ お問い合わせ
Multi User	￥900,000 (USD6,000)	▷ お問い合わせ
Enterprise License	￥1,200,000 (USD8,000)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYリサーチ社の本調査レポートでは、世界のI型高脂血症治療薬市場について種類別（アリポジーン・チパルボベック、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラジガスタットナトリウム、その他）、用途別（病院、クリニック、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・I型高脂血症治療薬市場の概要 ・世界の主要地域別I型高脂血症治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のI型高脂血症治療薬市場規模2015-2026：種類別（アリポジーン・チパルボベック、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラジガスタットナトリウム、その他） ・世界のI型高脂血症治療薬市場規模2015-2026：用途別（病院、クリニック、その他） ・I型高脂血症治療薬の米国市場規模2015-2020 ・I型高脂血症治療薬のヨーロッパ市場規模2015-2020 ・I型高脂血症治療薬の中国市場規模2015-2020 ・I型高脂血症治療薬の日本市場規模2015-2020 ・I型高脂血症治療薬の東南アジア市場規模2015-2020 ・I型高脂血症治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・I型高脂血症治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・I型高脂血症治療薬の市場動向・機会・課題 ・調査の結論

Market Analysis and Insights: Global Type I Hyperlipoproteinemia Drug Market
The global Type I Hyperlipoproteinemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Type I Hyperlipoproteinemia Drug Scope and Market Size
The global Type I Hyperlipoproteinemia Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Type I Hyperlipoproteinemia Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Type I Hyperlipoproteinemia Drug market is segmented into
Alipogene Tiparvovec
CAT-2003
ISIS-APOCIIIRx
Lomitapide Mesylate
Pradigastat Sodium
Others

Segment by Application, the Type I Hyperlipoproteinemia Drug market is segmented into
Hospital
Clinic
Others

The Type I Hyperlipoproteinemia Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Type I Hyperlipoproteinemia Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Type I Hyperlipoproteinemia Drug Market Share Analysis
Type I Hyperlipoproteinemia Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Type I Hyperlipoproteinemia Drug business, the date to enter into the Type I Hyperlipoproteinemia Drug market, Type I Hyperlipoproteinemia Drug product introduction, recent developments, etc.

The major vendors covered:
Aegerion Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Novartis AG
uniQure N.V.

レポート目次

---

1 Type I Hyperlipoproteinemia Drug Market Overview
1.1 Type I Hyperlipoproteinemia Drug Product Scope
1.2 Type I Hyperlipoproteinemia Drug Segment by Type
1.2.1 Global Type I Hyperlipoproteinemia Drug Sales by Type (2020-2026)
1.2.2 Alipogene Tiparvovec
1.2.3 CAT-2003
1.2.4 ISIS-APOCIIIRx
1.2.5 Lomitapide Mesylate
1.2.6 Pradigastat Sodium
1.2.7 Others
1.3 Type I Hyperlipoproteinemia Drug Segment by Application
1.3.1 Global Type I Hyperlipoproteinemia Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Type I Hyperlipoproteinemia Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Type I Hyperlipoproteinemia Drug Sales Growth Rate (2015-2026)
1.4.2 Global Type I Hyperlipoproteinemia Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Type I Hyperlipoproteinemia Drug Price Trends (2015-2026)

2 Type I Hyperlipoproteinemia Drug Estimate and Forecast by Region
2.1 Global Type I Hyperlipoproteinemia Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Type I Hyperlipoproteinemia Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Type I Hyperlipoproteinemia Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region (2015-2020)
2.3 Global Type I Hyperlipoproteinemia Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Type I Hyperlipoproteinemia Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Type I Hyperlipoproteinemia Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
2.4.2 Europe Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
2.4.3 China Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
2.4.4 Japan Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
2.4.6 India Type I Hyperlipoproteinemia Drug Estimates and Projections (2015-2026)
3 Global Type I Hyperlipoproteinemia Drug Competition Landscape by Players
3.1 Global Top Type I Hyperlipoproteinemia Drug Players by Sales (2015-2020)
3.2 Global Top Type I Hyperlipoproteinemia Drug Players by Revenue (2015-2020)
3.3 Global Type I Hyperlipoproteinemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Type I Hyperlipoproteinemia Drug as of 2019)
3.4 Global Type I Hyperlipoproteinemia Drug Average Price by Company (2015-2020)
3.5 Manufacturers Type I Hyperlipoproteinemia Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Type I Hyperlipoproteinemia Drug Players (Opinion Leaders)
4 Global Type I Hyperlipoproteinemia Drug Market Size by Type
4.1 Global Type I Hyperlipoproteinemia Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Type I Hyperlipoproteinemia Drug Price by Type (2015-2020)
4.2 Global Type I Hyperlipoproteinemia Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Type I Hyperlipoproteinemia Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Type I Hyperlipoproteinemia Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Type I Hyperlipoproteinemia Drug Price Forecast by Type (2021-2026)
5 Global Type I Hyperlipoproteinemia Drug Market Size by Application
5.1 Global Type I Hyperlipoproteinemia Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Type I Hyperlipoproteinemia Drug Price by Application (2015-2020)
5.2 Global Type I Hyperlipoproteinemia Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Type I Hyperlipoproteinemia Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Type I Hyperlipoproteinemia Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Type I Hyperlipoproteinemia Drug Price Forecast by Application (2021-2026)

6 United States Type I Hyperlipoproteinemia Drug Market Facts & Figures
6.1 United States Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
6.2 United States Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
6.3 United States Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

7 Europe Type I Hyperlipoproteinemia Drug Market Facts & Figures
7.1 Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
7.2 Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
7.3 Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

8 China Type I Hyperlipoproteinemia Drug Market Facts & Figures
8.1 China Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
8.2 China Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
8.3 China Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

9 Japan Type I Hyperlipoproteinemia Drug Market Facts & Figures
9.1 Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Company (3015-3030)
9.2 Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
9.3 Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

10 Southeast Asia Type I Hyperlipoproteinemia Drug Market Facts & Figures
10.1 Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

11 India Type I Hyperlipoproteinemia Drug Market Facts & Figures
11.1 India Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
11.2 India Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
11.3 India Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Type I Hyperlipoproteinemia Drug Business
12.1 Aegerion Pharmaceuticals, Inc.
12.1.1 Aegerion Pharmaceuticals, Inc. Corporation Information
12.1.2 Aegerion Pharmaceuticals, Inc. Business Overview
12.1.3 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Products Offered
12.1.5 Aegerion Pharmaceuticals, Inc. Recent Development
12.2 Catabasis Pharmaceuticals, Inc.
12.2.1 Catabasis Pharmaceuticals, Inc. Corporation Information
12.2.2 Catabasis Pharmaceuticals, Inc. Business Overview
12.2.3 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Products Offered
12.2.5 Catabasis Pharmaceuticals, Inc. Recent Development
12.3 Isis Pharmaceuticals, Inc.
12.3.1 Isis Pharmaceuticals, Inc. Corporation Information
12.3.2 Isis Pharmaceuticals, Inc. Business Overview
12.3.3 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Products Offered
12.3.5 Isis Pharmaceuticals, Inc. Recent Development
12.4 Novartis AG
12.4.1 Novartis AG Corporation Information
12.4.2 Novartis AG Business Overview
12.4.3 Novartis AG Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Novartis AG Type I Hyperlipoproteinemia Drug Products Offered
12.4.5 Novartis AG Recent Development
12.5 uniQure N.V.
12.5.1 uniQure N.V. Corporation Information
12.5.2 uniQure N.V. Business Overview
12.5.3 uniQure N.V. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 uniQure N.V. Type I Hyperlipoproteinemia Drug Products Offered
12.5.5 uniQure N.V. Recent Development
…

13 Type I Hyperlipoproteinemia Drug Manufacturing Cost Analysis
13.1 Type I Hyperlipoproteinemia Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug
13.4 Type I Hyperlipoproteinemia Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Type I Hyperlipoproteinemia Drug Distributors List
14.3 Type I Hyperlipoproteinemia Drug Customers

15 Market Dynamics
15.1 Type I Hyperlipoproteinemia Drug Market Trends
15.2 Type I Hyperlipoproteinemia Drug Opportunities and Drivers
15.3 Type I Hyperlipoproteinemia Drug Market Challenges
15.4 Type I Hyperlipoproteinemia Drug Market Restraints
15.5 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Type I Hyperlipoproteinemia Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Region (2015-2020)
Table 6. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Type I Hyperlipoproteinemia Drug Revenue Share by Region (2015-2020)
Table 8. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Type I Hyperlipoproteinemia Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Type I Hyperlipoproteinemia Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Type I Hyperlipoproteinemia Drug Sales Share by Company (2015-2020)
Table 14. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Type I Hyperlipoproteinemia Drug Revenue Share by Company (2015-2020)
Table 16. Global Type I Hyperlipoproteinemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Type I Hyperlipoproteinemia Drug as of 2019)
Table 17. Global Type I Hyperlipoproteinemia Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Type I Hyperlipoproteinemia Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Type I Hyperlipoproteinemia Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Type I Hyperlipoproteinemia Drug Players
Table 22. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Type I Hyperlipoproteinemia Drug Sales Share by Type (2015-2020)
Table 24. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Type I Hyperlipoproteinemia Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Type I Hyperlipoproteinemia Drug Sales Share by Type (2021-2026)
Table 27. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Type I Hyperlipoproteinemia Drug Revenue Share by Type (2021-2026)
Table 29. Global Type I Hyperlipoproteinemia Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Type I Hyperlipoproteinemia Drug Sales Share by Application (2015-2020)
Table 32. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Type I Hyperlipoproteinemia Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Type I Hyperlipoproteinemia Drug Sales Share by Application (2021-2026)
Table 36. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Type I Hyperlipoproteinemia Drug Revenue Share by Application (2021-2026)
Table 38. Global Type I Hyperlipoproteinemia Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 41. United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 43. United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 51. China Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 53. China Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 55. China Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
Table 69. India Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Type I Hyperlipoproteinemia Drug Sales Market Share by Company (2015-2020)
Table 71. India Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2015-2020)
Table 73. India Type I Hyperlipoproteinemia Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2015-2020)
Table 75. Aegerion Pharmaceuticals, Inc. Corporation Information
Table 76. Aegerion Pharmaceuticals, Inc. Description and Business Overview
Table 77. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product
Table 79. Aegerion Pharmaceuticals, Inc. Recent Development
Table 80. Catabasis Pharmaceuticals, Inc. Corporation Information
Table 81. Catabasis Pharmaceuticals, Inc. Description and Business Overview
Table 82. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product
Table 84. Catabasis Pharmaceuticals, Inc. Recent Development
Table 85. Isis Pharmaceuticals, Inc. Corporation Information
Table 86. Isis Pharmaceuticals, Inc. Description and Business Overview
Table 87. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product
Table 89. Isis Pharmaceuticals, Inc. Recent Development
Table 90. Novartis AG Corporation Information
Table 91. Novartis AG Description and Business Overview
Table 92. Novartis AG Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Novartis AG Type I Hyperlipoproteinemia Drug Product
Table 94. Novartis AG Recent Development
Table 95. uniQure N.V. Corporation Information
Table 96. uniQure N.V. Description and Business Overview
Table 97. uniQure N.V. Type I Hyperlipoproteinemia Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. uniQure N.V. Type I Hyperlipoproteinemia Drug Product
Table 99. uniQure N.V. Recent Development
Table 100. Production Base and Market Concentration Rate of Raw Material
Table 101. Key Suppliers of Raw Materials
Table 102. Type I Hyperlipoproteinemia Drug Distributors List
Table 103. Type I Hyperlipoproteinemia Drug Customers List
Table 104. Type I Hyperlipoproteinemia Drug Market Key Trends
Table 105. Type I Hyperlipoproteinemia Drug Key Opportunities and Drivers
Table 106. Type I Hyperlipoproteinemia Drug Market Challenges
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Type I Hyperlipoproteinemia Drug Product Picture
Figure 2. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Type I Hyperlipoproteinemia Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Others Examples
Figure 9. Global Type I Hyperlipoproteinemia Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Type I Hyperlipoproteinemia Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Type I Hyperlipoproteinemia Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Type I Hyperlipoproteinemia Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Type I Hyperlipoproteinemia Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Type I Hyperlipoproteinemia Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Type I Hyperlipoproteinemia Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Type I Hyperlipoproteinemia Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Type I Hyperlipoproteinemia Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Type I Hyperlipoproteinemia Drug Players Market Share by Revenue in Type I Hyperlipoproteinemia Drug 2015 & 2019
Figure 27. Type I Hyperlipoproteinemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Type I Hyperlipoproteinemia Drug Revenue Share by Type (2015-2020)
Figure 29. Global Type I Hyperlipoproteinemia Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Type I Hyperlipoproteinemia Drug Revenue Share by Application (2015-2020)
Figure 31. Global Type I Hyperlipoproteinemia Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 33. United States Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 34. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Company in 2019
Figure 35. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 36. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2019
Figure 37. China Type I Hyperlipoproteinemia Drug Sales Market Share by Company in 2019
Figure 38. China Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 39. China Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2019
Figure 40. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Company in 2019
Figure 41. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 42. Japan Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2019
Figure 46. India Type I Hyperlipoproteinemia Drug Sales Market Share by Company in 2019
Figure 47. India Type I Hyperlipoproteinemia Drug Sales Market Share by Type in 2019
Figure 48. India Type I Hyperlipoproteinemia Drug Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Type I Hyperlipoproteinemia Drug
Figure 51. Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug
Figure 52. Type I Hyperlipoproteinemia Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

---